Retracted : Protective effects of microRNA‐330 on amyloid β‐protein production, oxidative stress, and mitochondrial dysfunction in Alzheimer's disease by targeting VAV1 via the MAPK signaling pathway
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
This study aims to explore the effect of miR‐330 targeting VAV1 on amyloid β‐protein (Aβ) production, oxidative stress (OS), and mitochondrial dysfunction in Alzheimer's disease (AD) mice through the MAPK signaling pathway. Putative targeted gene of miR‐330 was performed by a miRNA target prediction website and dual‐luciferase reporter gene assay. AD mouse model was successfully established. Fourteen C57 mice were randomized into AD and control groups. The positive protein expression rate of VAV1 was measured by immunohistochemistry. Neuron cells were assigned into control, blank, negative control (NC), miR‐330 mimics, miR‐330 inhibitors, siRNA‐VAV1, and miR‐330 inhibitors + siRNA‐VAV1 groups. Expression of miR‐330, VAV1, ERK1, JNK1, P38MAPK, Aβ, COX, and lipoprotein receptor‐related protein‐1 (LRP‐1) were determined using RT‐qPCR and Western blotting. Colorimetry was applied to measure the levels of OS parameters of superoxide dismutase (SOD) and malondialdehyde (MDA). Aβ production in brain tissue was detected using ELISA, while that in neuron cell was measured by radioimmunoassay. MiR‐330 was down‐regulated in neuron cells of AD mice and VAV1 was negatively regulated by miR‐330. Compared with the control group, the positive protein expression rate of VAV1 was significantly elevated in the AD group. Overexpression of miR‐330 decreased the expression of VAV1, ERK1, JNK1, P38MAPK, and Aβ, but increased the expression of COX and LRP‐1. AD mice revealed elevated Aβ production and MDA with decreased SOD level. The result indicates that overexpressed miR‐330 targeting VAV1 through the MAPK signaling pathway reduces Aβ production and alleviates OS and mitochondrial dysfunction in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks
Palop, J. J., & Mucke, L. (2010) · Nature Neuroscience · doi:10.1038/nn.2583 · Cited by 1,651 · cited 1×
“The pathogenesis and progression of AD might be closely related to many risk factors, such as the insufficiency of Vitamin D, vascular alteration, inflammation, oxidative stress, epigenetic determinants and environmental factors, all of which play important co-pathogenic roles in the brain function.(3,4) Especially, A…”
BackgroundA Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Inflammation and Alzheimer’s disease
Lee, Y.-J., Han, S. B., Nam, S.-Y., Oh, K.-W., & Hong, J. T. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-1006-7 · Cited by 396
MicroRNAs in Alzheimer's disease
Delay, C., Mandemakers, W., & Hébert, S. S. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.01.003 · Cited by 185
Linking Alzheimer's disease to insulin resistance: the FoxO response to oxidative stress
Manolopoulos, K. N., Klotz, L.-O., Korsten, P., Bornstein, S. R., & Barthel, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2010.17 · Cited by 150
Cited by
MicroRNAs in Alzheimer’s Disease
Wang, M., Qin, L., & Tang, B. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00153 · Cited by 307
MicroRNAs in Alzheimer’s Disease: Function and Potential Applications as Diagnostic Biomarkers
Wei, W., Wang, Z.-Y., Ma, L.-N., Zhang, T.-T., Cao, Y., & Li, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00160 · Cited by 103
Self-citationCell toxicity mechanism and biomarker
Zhang, Y. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0212-7 · Cited by 89
Ravanidis, S., Bougea, A., Papagiannakis, N., Maniati, M., Koros, C., Simitsi, A., Bozi, M., Pachi, I., Stamelou, M., Paraskevas, G. P., et al. (2020) · Movement Disorders · doi:10.1002/mds.27928 · Cited by 51
MiR-9-5p inhibits mitochondrial damage and oxidative stress in AD cell models by targeting GSK-3β
Liu, J., Zuo, X., Han, J., Dai, Q., Xu, H., Liu, Y., & Cui, S. (2020) · Bioscience, Biotechnology, and Biochemistry · doi:10.1080/09168451.2020.1797469 · Cited by 50
Metadata
- Authors
- Zhou, Y., Wang, Z., Li, W., Hong, H., Chen, J., Tian, Y., & Liu, Z.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2018-04-06
- Volume
- 119
- Issue
- 7
- Pages
- 5437-5448
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W2794203475
- Cited by
- 59
- References
- 7
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.